Cargando…

O(6)-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents

BACKGROUND: O(6)-Methylguanine-DNA methyltransferase (MGMT) loss of expression has been suggested to be predictive of response to temozolomide in neuroendocrine tumours (NETs), but so far, only limited data are available. We evaluated the prognostic and predictive value of MGMT status, assessed by t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, T, van Brakel, B, Vercherat, C, Hervieu, V, Forestier, J, Chayvialle, J-A, Molin, Y, Lombard-Bohas, C, Joly, M-O, Scoazec, J-Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453664/ https://www.ncbi.nlm.nih.gov/pubmed/25584486 http://dx.doi.org/10.1038/bjc.2014.660

Ejemplares similares

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
por: Cambien, B, et al.
Publicado: (2009)

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
por: Quintela-Fandino, M, et al.
Publicado: (2013)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model
por: Julien, S, et al.
Publicado: (2009)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
por: Broadhead, M L, et al.
Publicado: (2011)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil
por: Chen, C-C, et al.
Publicado: (2007)

Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review
por: Boland, J W, et al.
Publicado: (2014)

PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
por: Shen, B, et al.
Publicado: (2012)

Downregulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma
por: Liu, S J, et al.
Publicado: (2008)

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer
por: Collins, L, et al.
Publicado: (2006)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells
por: Zhu, T, et al.
Publicado: (2007)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
por: Yeow, W-S, et al.
Publicado: (2006)

O(6)-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma
por: Bobola, Michael S., et al.
Publicado: (2014)

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
por: Wang, L-H, et al.
Publicado: (2014)

An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
por: Lee, H E, et al.
Publicado: (2011)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells
por: Jeon, T-Y, et al.
Publicado: (2010)

Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers
por: Freis, Patricia, et al.
Publicado: (2017)

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
por: Storozhuk, Y, et al.
Publicado: (2013)

Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer
por: Cheng, Y Y, et al.
Publicado: (2007)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice
por: Wehenkel, M, et al.
Publicado: (2012)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
por: Yoon, C, et al.
Publicado: (2015)

CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2
por: Chang, G, et al.
Publicado: (2014)

The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors
por: Bollard, Julien, et al.
Publicado: (2015)

Human fucosyltransferase 6 enables prostate cancer metastasis to bone
por: Li, J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5vlpajonf5dicvbsm7iumipefs